Biocon Ltd.

Biocon Limited was facing significant price pressure in their cash cow business, which consisted primarily of the manufacture of Active Pharmaceutical Ingredients (APIs). To combat this commoditization had chosen an innovation-led strategy Biocon’s leadership. This new strategy consisted of licensing and development of good molecules from strategic partners to overtake the competition and create large molecule biologics in India. The company is understood that the transition from an API to an innovation-led … Read more »

Biocon Limited was facing significant price pressure in their cash cow business, which consisted primarily of the manufacture of Active Pharmaceutical Ingredients (APIs). To combat this commoditization had chosen an innovation-led strategy Biocon’s leadership. This new strategy consisted of licensing and development of good molecules from strategic partners to overtake the competition and create large molecule biologics in India. The company is understood that the transition from an API to an innovation-led company would focus on new biologics require patience and risk tolerance mindset. Although there were some similarities in the biochemical engineering aspects of both approaches, regulatory approvals, product development and market access paths timelines were dramatically different – almost diametrically opposed. Analyzed Biocon’s strategic decisions and the risks and challenges associated with the migration from a manufacturing to an innovation-led company. How would they balance short-term pragmatism against long-term vision? They have to scale the appropriate human resources and innovate? Is their India-centric strategy makes sense, since 86% of the end-market demand in the U.S., Europe and Japan? Fortunately, the first signs of their innovation-led strategy with positive signs and demonstrable results – how their biogenetic insulin and monoclonal antibodies launch in India. The projection oral insulin project with a planned $ 100 million budget, met his milestones and deliverables. Many critical business challenges are described in this case. Nevertheless, given its fully integrated business model and significant production site, chances are in favor with Biocon to meet these challenges and lead India’s biotech revolution.
This case is only available in printed form (HBP no digital distribution rights to the content) are available. As a result, a digital copy of the Educator case via this website is not available.
«Hide

from
Krishna G. Palepu,
Ananth K. Chepuri
Source: Harvard Business School
35 pages.
Release Date: 29 May 2007. Prod #: 107083-HCB-ENG
Biocon Ltd. HBR case solution